肝损伤
基因敲除
医学
肝保护
下调和上调
药理学
对乙酰氨基酚
癌症研究
肝炎
免疫学
背景(考古学)
炎症
胆汁淤积
肝癌
氧化应激
肝细胞
重型肝炎
生物
中毒性肝炎
酒精性肝炎
CYP2E1
肝病
调节器
作者
Yong Won Choi,Jae Ho Choi,Young-Sam Lee,Jinju Jeong,Eunho Kang,So Hyun Park,Young‐Kyoung Lee,Soon Sang Park,Hee Young Kang,Young Hwa Kim,Tae Jun Park
标识
DOI:10.1016/j.ymthe.2026.01.010
摘要
Drug-induced liver injury accounts for approximately 10% of acute hepatitis and up to 50% of acute liver failure. Despite its clinical significance, treatment remains largely limited to cessation of the offending agent. SLIT/ROBO signaling, known for roles in organ development, angiogenesis, leukocyte migration, and cancer metastasis, has demonstrated protective effects against various organ damage. In mouse models of liver injury induced by acetaminophen (APAP), thioacetamide, bile duct ligation, and serum from patients with toxic liver disease, Slit2 expression significantly increases, while Slit1 and Slit3 remain unchanged. Liver-specific Slit2 knockdown exacerbates liver injury, whereas recombinant SLIT2 alleviates liver damage by reducing oxidative stress via CYP2E1 downregulation and suppressing inflammation through nuclear factor κB inhibition. Notably, among ROBO receptors, only ROBO4 was induced in hepatocytes after APAP exposure. ROBO4 knockdown eliminates the hepatoprotective effects of SLIT2, highlighting the importance of SLIT2/BOBO4 signaling in toxic liver injury. Furthermore, the novel Slit2-derived peptide 5 (SP5), designed from the ROBO4-binding LRR2 domain, significantly reduces liver damage and inflammation. Notably, both recombinant SLIT2 and SP5 confer hepatoprotection even when administered 24 h after APAP challenge. These findings suggest that SLIT2/ROBO4-targeted therapies may offer a promising approach for preventing fulminant hepatitis in the context of toxic liver injury.
科研通智能强力驱动
Strongly Powered by AbleSci AI